Welcome to our dedicated page for The Oncology Institute news (Ticker: TOIIW), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute Inc (NASDAQ: TOIIW) delivers community-focused cancer care through innovative value-based models and clinical research integration. This news hub provides investors and healthcare professionals with essential updates on operational developments, strategic partnerships, and patient care advancements.
Access authoritative reporting on TOI's financial performance, clinical trial milestones, and service expansions. Our curated collection includes press releases covering earnings announcements, new clinic openings, research collaborations, and healthcare policy impacts relevant to oncology care delivery.
Key updates feature developments in infusion center operations, progress in value-based payment models, and community health initiatives. Stay informed about TOI's role in outpatient cancer treatment innovation and its growing network of care centers across strategic regions.
Bookmark this page for real-time access to verified TOIIW disclosures and analysis-free reporting. Check regularly for essential updates that matter to stakeholders in oncology care and value-driven healthcare investments.
The Oncology Institute (NASDAQ: TOI) reported Q3 2025 results and raised full‑year guidance on Nov 13, 2025. Consolidated revenue was $136.6M, up 36.7% year‑over‑year; gross profit was $18.9M, up 31.7%. Retail pharmacy set fill records, contributing $75.9M revenue and $12.8M gross profit in Q3. Net loss was $16.5M and basic/diluted loss per share was $0.14. Adjusted EBITDA improved to $(3.5)M in Q3; cash and cash equivalents were $27.7M at quarter end.
TOI updated 2025 guidance: revenue to $495–505M (from $460–480M) and Adjusted EBITDA to $(11)–$(13)M (from $(8)–$(17)M); Q4 Adjusted EBITDA is expected around $0–$2M. The company noted continued organic growth in Florida and Oregon and a new CAO hire for operations and AI enablement. A conference call and webcast were scheduled for Nov 13, 2025 at 5:00 p.m. ET.
Ascertain and The Oncology Institute (NASDAQ: TOI) announced a co-development to deploy a “near-touchless” prior authorization workflow using Ascertain’s Unified Payer Portal.
The joint team moved from signed statement of work to a live early-stage deployment in eight weeks, with the system live since September 2025. Pilot sites saw a >80% reduction in office-visit authorization submission time and the program freed hundreds of staff hours each week. The portal now processes prior authorizations across TOI’s 100+ clinics and affiliates. TOI estimates the initiative could yield up to $2 million in operating expense savings in 2026 as the solution scales to additional authorization types.
The Oncology Institute (NASDAQ: TOI) will release its third quarter 2025 financial results after market close on Thursday, November 13, 2025.
A company conference call will follow the same day at 5:00 p.m. Eastern Time, accessible by phone or simultaneous webcast on the company Investor Relations website. A replay will be available two hours after the call through Thursday, November 20, 2025. The passcode for both the live call and replay is 13756737.
The Oncology Institute (NASDAQ:TOI), a leader in value-based community oncology care, will participate in the Noble Capital Markets Emerging Growth Virtual Equity Conference. CEO Dr. Daniel Virnich and CFO Rob Carter will deliver a presentation on October 8, 2025 at 11:00 AM ET.
Investors can access the presentation webcast by registering through the company's Investor Relations website at investors.theoncologyinstitute.com.
The Oncology Institute (NASDAQ: TOI) has partnered with Protocol Behavioral Health to integrate mental health services into cancer care delivery. The collaboration aims to address the significant mental health challenges faced by cancer patients, with research showing that approximately 30% of cancer patients experience depression or anxiety.
Through this partnership, TOI patients will receive immediate access to specialized mental health services, offered in multiple languages and fully integrated into their cancer treatment plans. The partnership utilizes the Collaborative Care Model (CoCM), an evidence-based framework for team-based care delivery that has been shown to improve treatment adherence, quality of life, and patient satisfaction.
The Oncology Institute (NASDAQ: TOI) has reported significant Medicare savings of $1.1 million during Performance Period 2 of the CMS Enhancing Oncology Model (EOM) through its California professional corporation. The company achieved savings of over $3,500 per patient episode and earned maximum scores for reducing avoidable emergency department visits and hospital admissions.
The success was attributed to TOI's High Value Cancer Care program, featuring Health Care Coaches and 24/7 symptom management support. This performance builds on TOI's previous achievements in CMS's Oncology Care Model, where it exceeded quality standards and generated multi-million-dollar Medicare savings.
The Oncology Institute (NASDAQ: TOI) has announced the launch of its Lung Cancer Center of Excellence in Fort Lauderdale, Florida. The center will be led by renowned thoracic oncologist Dr. Edgardo S. Santos Castillero, an internationally recognized expert in the field.
The new center aims to provide advanced cancer treatments and clinical trials in a community-based setting, making high-quality care more accessible to Florida patients. Dr. Santos brings extensive experience from leadership roles at prestigious institutions including Tulane University and the University of Miami/Sylvester Comprehensive Cancer Center.
This initiative aligns with TOI's mission to expand access to value-based oncology care while reducing financial burden for patients and payors.
The Oncology Institute (NASDAQ: TOI) has announced a strategic partnership with Doctors HealthCare Plans to enhance oncology care management in South Florida. TOI will provide delegated utilization management services and clinical advisory support for the Medicare Advantage plan's members.
Under this collaboration, TOI will manage oncology services using its clinical protocols, medical director oversight, and technology-enabled workflows. The partnership aims to support optimal oncology benefit design and evidence-based care pathways, building on TOI's successful track record of managing medical cost risk across multiple states.
The partnership focuses on ensuring patients receive appropriate care while improving outcomes and maintaining cost effectiveness in the healthcare system.
The Oncology Institute (NASDAQ: TOI) reported strong Q2 2025 financial results, with consolidated revenue reaching $119.8 million, up 21.5% year-over-year. The company's pharmacy business showed exceptional growth of over 40%, while adding 50,000 new capitated lives.
Key financial metrics include gross profit of $17.5 million (up 34.4%), net loss of $17.0 million, and Adjusted EBITDA of $(4.1) million. TOI reaffirmed its full-year 2025 guidance, expecting revenue between $460-480 million and targeting the higher end of this range. The company anticipates reaching Adjusted EBITDA positivity by the end of 2025.
Strategic developments include planned expansion in Florida markets and a new capitation relationship with Silver Summit Health Plan in Nevada. TOI also welcomed new executive appointments to strengthen its clinical and administrative leadership.
The Oncology Institute (NASDAQ: TOI), one of the largest value-based oncology groups in the US, announced significant leadership changes to its Board of Directors. Richard Barasch will retire as Chairman of the Board, effective August 12, 2025, with Anne McGeorge, current Board Member and Audit Committee Chair, succeeding him.
McGeorge brings over 35 years of healthcare experience, notably having grown Grant Thornton LLP's Global Health Care and Life Sciences Practice into a $250 million global business. She currently serves on multiple boards including Dianthus Therapeutics (NASDAQ: DNTH), Nimbus Therapeutics, and CitiusTech.
Under Barasch's leadership, TOI successfully became a publicly traded company and expanded its business model beyond California.
FAQ
What is the current stock price of The Oncology Institute (TOIIW)?
